Parnax Lab DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22Mar 2022	FY21 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage					FY21 and earlierEvery year the company has filed comes with Alpha Plus.
	1.58×	1.19×	1.08×	0.59×
	16.7%	27.6%	20.1%	18.5%
	0.30×	0.34×	0.33×	0.35×

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

PARNAXLAB₹109.47

Parnax Lab Limited

· Pharma & Health

₹ CrorePeersBPLPHARMA JENBURPH KPL MAKERSL NOVARTIND SGRL SHUKRAPHAR SUNLOC

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY22 31/03/2022	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Interest Burden (Pretax/EBIT) ×	0.59	1.08	1.19	1.58
EBIT Margin %	18.51	20.14	27.59	16.70
Asset Turnover ×	0.35	0.33	0.34	0.30

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY25 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.